This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of 15.79% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 138.46% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn into More Strength?
by Zacks Equity Research
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
by Zacks Equity Research
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
Does ClearPoint Neuro (CLPT) Have the Potential to Rally 81.49% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 70.65% Upside in ClearPoint Neuro (CLPT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for ClearPoint Neuro (CLPT) points to a 70.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -6.90% and 0.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 21.25% and 10.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
by Zacks Equity Research
ClearPoint Neuro (CLPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 13.64% and 6.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint's (CLPT) Prism System Favored by Latest Study
by Zacks Equity Research
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 17.86% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of -1.11% and 0.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -75.38% and 2.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Shockwave Medical (SWAV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 26.09% and 1.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries
by Zacks Equity Research
ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.
Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.
How Much Upside is Left in ClearPoint Neuro, Inc. (CLPT)? Wall Street Analysts Think 48.77%
by Zacks Equity Research
The mean of analysts' price targets for ClearPoint Neuro, Inc. (CLPT) points to a 48.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ClearPoint Neuro, Inc. (CLPT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in OrthoPediatrics (KIDS): Can Its 8.1% Jump Turn into More Strength?
by Zacks Equity Research
OrthoPediatrics (KIDS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -61.11% and 0.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 34.38% and 10.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?